Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
Raju Kapoor(University College London Hospitals NHS Foundation Trust), Abdullatif Al Khedr, Gregg Blevins, Virender Bhan, Nisha Lucas(Biogen (United States)), Matthias Kant(Sygehus Sønderjylland), Dan Mikol(Biogen (United States)), Liesly Lee, Yves Lapierre, Mads Ravnborg(Odense University Hospital), Sarah A. Morrow(University of Calgary), Marika Talábová, Laura Airas(Turku University Hospital), Pei‐Ran Ho(The University of Sydney), Irina Elovaara(Tampere University), Pierre Duquette(Centre Hospitalier de l’Université de Montréal), Marie D’hooghe, A Miller(Icahn School of Medicine at Mount Sinai), François Grand’Maison, Ih Chang(Biogen (United States)), Petr Kaňovský(University Hospital Olomouc), Michael Yeung(University of Cambridge), François Jacques, Ivana Štětkářová, E Bartholomé, Douglas L. Arnold(McGill University), Nolan Campbell(Biogen (United States)), Myla Goldman(Virginia Commonwealth University), Aaron Deykin(Biogen (United States)), Fiona Forrestal(Biogen (United States)), Donald Brunet(Queen's University), Eva Havrdová(Charles University), Jette Lautrup Frederiksen(University of Copenhagen), Massimo Pandolfo(McGill University), Bei Yu(Biogen (United States)), Diego Cadavid(ID Genomics (United States)), Thor Petersen(Aarhus University Hospital), Virginia Devonshire, Bart Van Wijmeersch(National MS Center Melsbroek), Taneli Sarasoja, Deborah Steiner(Biogen (United States)), Douglas Jeffery(University of New Mexico), Juha-Pekka Erälinna(University of Turku), Hans-Peter Hartung(The University of Sydney), Michal Dufek, Mark S. Freedman(University of Ottawa), Finn Sellebjerg(Kaiser Permanente)
Cited by 345
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
|New England Journal of Medicine|2016|1.9k